Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00200421 · ClinicalTrials.gov registry record · Phase 2

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

A Phase 2 study of Hypertension, sponsored by Mylan Bertek Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
110
Enrollment target
1
Study location

NCT00200421: Completed Phase 2 study of Hypertension, sponsored by Mylan Bertek Pharmaceuticals.

NCT00200421 is a Phase 2 study of Hypertension that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 110 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00200421, a Phase 2 study of Hypertension, has completed, sponsored by Mylan Bertek Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effects on exercise capacity of nebivolol compared to atenolol in hypertensive patients.

Conditions Studied

Interventions

  • DRUG Nebivolol and Atenolol

Study Locations (1)

West Virginia

  • Mylan Pharmaceuticals Inc. - Morgantown

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2002-05
Est. Completion 2003-08
Phase Phase 2
Mylan Bertek Pharmaceuticals

10 total trials

What the finished NCT00200421 record still lists

NCT00200421 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Nebivolol and Atenolol is the first listed.

NCT00200421 reports a single indexed study location in West Virginia.

Frequently Asked Questions

What is clinical trial NCT00200421 about?

NCT00200421 is a clinical study titled "A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension". The purpose of this study is to determine the effects on exercise capacity of nebivolol compared to atenolol in hypertensive patients.

What is the current status of trial NCT00200421?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2002-05. Estimated completion is 2003-08.

What conditions does trial NCT00200421 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00200421?

The interventions under investigation include: Nebivolol and Atenolol (DRUG).

Who is sponsoring clinical trial NCT00200421?

This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00200421 being conducted?

This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00200421's enrollment target sits among peer trials

110 280th of 470 higher than 188 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT02411773 · 110 participants · Phase 1

    Sympatholysis in Chronic Kidney Disease

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00200421, the US trial registry maintained by the National Library of Medicine. NCT00200421 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.